Career News: 13 Japanese companies to attend JAPAN DAY 2021 @IIT Hyderabad  |  Higher Studies: IELTS Mock Tests: Benefits and Characteristics  |  Teacher Insights: New Features in Moodle 4.0  |  Policy Indications: India-US Launch Climate Action and Finance Mobilisation Dialogue  |  Science Innovations: Stanford University Develops Algorithm to Predict Molecular Structures  |  Technology Inceptions: Oxygen Concentrator, Generation System Developed by Indian Institute of Science  |  Teacher Insights: Early Intervention in Children Good to Prevent Dyslexia  |  Parent Interventions: Cognitive Stimulation Lowers Dementia Risk  |  Parent Interventions: Elderly Cope Better with Pandemic  |  Policy Indications: Use of Copyrighted Works in Online Education  |  Parent Interventions: Maternal Voice Reduces Pain in Preemies  |  Teacher Insights: Eye Sight of Children Affected by Online Learning  |  Expert Counsel: Afghanistan: Top Trouble Spot  |  Best Practices: 'Money Box' Project Gets National Recognition  |  Best Practices: Craft World School Support in Fighting Pandemic  |  
January 05, 2021 Tuesday 11:08:22 AM IST

DNA Vaccine Candidate by Zydus Cadila, approved for Phase III clinical trials

Science Innovations

The Nation’s first indigenously developed DNA vaccine candidate against COVID-19, ZyCoV-D, by M/s Zydus Cadila has been approved by Drugs Controller General of India (DCGI), for the conduct of Phase III clinical trials. The candidate has been supported by the National Biopharma Mission (NBM) under the aegis of BIRAC and the Department of Biotechnology, Government of India.

Zydus Cadila completed Phase-I/II clinical trials of this DNA Vaccine candidate, in India, in more than 1,000 participants and interim data indicated that the vaccine is safe and immunogenic when three doses were administered intradermally. Based on the recommendations of the Subject Expert Committee, which reviewed the interim data, the DCGI has accorded permission for conducting Phase-III clinical trial in 26,000 Indian participants.

Dr. Renu Swarup, Secretary, DBT, and Chairperson, BIRAC expressed happiness and hoped that the candidate vaccine continues to show positive outcomes. Speaking on the occasion, she said, “The Department of Biotechnology, Government of India has partnered with Zydus Cadila, to address the need for accelerated development of an indigenous vaccine for COVID-19. The partnership exemplifies that such research endeavours demonstrate the Government’s focus on creating an ecosystem that nurtures and encourages new product innovation with societal relevance”. She also mentioned, “The establishment of the Nation’s first DNA vaccine platform is an important milestone for Atma Nirbhar Bharat and a big leap forward for Indian scientific research.”


Comments